Off-label AMD therapies

Article

What are doctors using off-label to treat their AMD patients?

                                       

Avastin (Genentech): Anti-VEGF

Avastin (bevacizumab) is a recombitant humanized, full-length, anti-VEGF monoclonal antibody that binds all isoforms of VEGF-A. Although it is currently only approved for the treatment of colorectal and lung cancer, it is being widely used, off-label, for treatin wet AMD.

In May 2007, the Italian Pharmaceutical Agency (AIFA) announced the reimbursement of Avastin for the treatment of exudative maculopathy and neovascular glaucoma. As such, the agent, which has not been approved for this indication, would be fully reimbursed for use in Italian patients. Click here to read two experts opposing view of this decision.

The manufacturers of Avastin, Genentech, are now trying to prevent the drug being used off-label in the US by restricting sales to independent compounding pharmacies, which divide vials of the drug into smaller portions for use by ophthalmologists. This decision has caused uproar among US retina specialists.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.